Natera Announces New MRD Data in Multiple Tumor Types, to be Presented at ASCO Annual Meeting

Business Wire05-23

AUSTIN, Texas, May 23, 2024--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that the company, along with its collaborators, will ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2437875561?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/vmrNt2rQdqSBLxSdwc.RUw--~B/aD0yMDA7dz0yMDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/3ed92a46d4ad821156fb8a4d10198e13","is_english":true,"pubTime":"2024-05-23 19:30","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2437875561","market":"us","top_or_hot":-1,"title":"Natera Announces New MRD Data in Multiple Tumor Types, to be Presented at ASCO Annual Meeting","media":"Business Wire","content":"<div>\n<p>AUSTIN, Texas, May 23, 2024--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that the company, along with its collaborators, will ...</p>\n\n<a href=\"https://finance.yahoo.com/news/natera-announces-mrd-data-multiple-113000243.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Natera Announces New MRD Data in Multiple Tumor Types, to be Presented at ASCO Annual Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNatera Announces New MRD Data in Multiple Tumor Types, to be Presented at ASCO Annual Meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-23 19:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/natera-announces-mrd-data-multiple-113000243.html><strong>Business Wire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AUSTIN, Texas, May 23, 2024--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that the company, along with its collaborators, will ...</p>\n\n<a href=\"https://finance.yahoo.com/news/natera-announces-mrd-data-multiple-113000243.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4581","symbol_name":"高盛持仓","start_time":0,"source_url":"https://finance.yahoo.com/news/natera-announces-mrd-data-multiple-113000243.html","article_id":"2437875561","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/vmrNt2rQdqSBLxSdwc.RUw--~B/aD0yMDA7dz0yMDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/3ed92a46d4ad821156fb8a4d10198e13"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2437875561","pubTimestamp":1716463800,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"AUSTIN, Texas, May 23, 2024----Natera, Inc. , a global leader in cell-free DNA and genetic testing, today announced that the company, along with its collaborators, will present new data at the 2024 American Society of Clinical Oncology  Annual Meeting taking place May 31 – June 4, 2024.Minetta Liu, MD, chief medical officer of oncology at Natera, said, \"We look forward to sharing new data across cancer types, reflecting Natera's deep clinical pipeline in MRD with results from randomized trials as well as real-world studies. This includes promising new findings from the CIRCULATE-Japan GALAXY study demonstrating the prognostic and predictive utility of Signatera and actionable biomarkers in colorectal cancer.\". Poster Presentation | Abstract # 4028 | Presenter: Aziz Zaanan, MD | Esophageal CancerLongitudinal ctDNA analysis during treatment  of locally advanced resectable  gastric or gastroesophageal junction  adenocarcinoma : the PLAGAST prospective biomarker study","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4581":"高盛持仓","BK4139":"生物科技","CRC":"加州资源","BK4190":"消闲用品","BK4213":"石油与天然气的勘探与生产","BC":"宾士域","BK4588":"碎股","EBC":"Eastern Bankshares Inc","BK4590":"PTP","BK4211":"区域性银行","NAT":"Nordic American Tanker","NTRA":"Natera, Inc.","BK4144":"石油与天然气的储存和运输","ET":"Energy Transfer LP","CLIA":"VERIDIEN CLIMATE ACTION ETF","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","BK4585":"ETF&股票定投概念","BK4561":"索罗斯持仓"},"translate_title":"Natera宣布多种肿瘤类型的新MRD数据，将在ASCO年会上发表","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NTRA":1,"NAT":1,"ET":1,"EBC":1,"CRC":1,"CLIA":1,"BC":1},"content_text":"AUSTIN, Texas, May 23, 2024--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that the company, along with its collaborators, will present new data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31 – June 4, 2024.\nThe presentations feature data across a variety of indications, including breast cancer, colorectal cancer (CRC), lung cancer, melanoma, esophageal cancer, and urothelial cancer, with one oral presentation and 12 poster presentations on Signatera™, Natera’s personalized and tumor-informed molecular residual disease test, as well as one poster with data on Empower™, Natera’s test for hereditary cancer.\nMinetta Liu, MD, chief medical officer of oncology at Natera, said, \"We look forward to sharing new data across cancer types, reflecting Natera's deep clinical pipeline in MRD with results from randomized trials as well as real-world studies. This includes promising new findings from the CIRCULATE-Japan GALAXY study demonstrating the prognostic and predictive utility of Signatera and actionable biomarkers in colorectal cancer.\"\nGALAXY is part of the CIRCULATE-Japan trial platform, which also includes ALTAIR, a first-of-its-kind, \"treat on molecular recurrence\" study evaluating the utility of Signatera in CRC. Natera expects to announce topline results for this phase III randomized trial in August 2024.\nBelow is the full list of presentations featuring Signatera and Empower at ASCO:\n\nPoster Presentation | Abstract # 3609 | Presenter: Yoshiaki Nakamura, MD, PhD | CRCPrognostic and predictive value of ctDNA-based MRD and actionable biomarkers in patients with resectable CRC: CIRCULATE-Japan GALAXY\n\n\nOral Presentation | Abstract # LBA507 | Presenter: Sherene Loi, MD, PhD | Breast CancerPrognostic utility of ctDNA dynamics in the monarchE trial of adjuvant abemaciclib plus endocrine therapy (ET) in HR+, HER2-, node-positive, high-risk early breast cancer (EBC)\n\n\nPoster Presentation | Abstract # 3586 | Presenter: Eric Lander, MD | CRCGenomic alterations in early-onset versus average-onset stage IV CRC\n\n\nPoster Presentation | Abstract # 5034 | Presenter: Rebecca Hassoun, MD | Testicular CancerLongitudinal Evaluation of ctDNA as a Prognostic Biomarker to Detect Minimal Residual Disease (MRD) in Testicular Cancer\n\n\nPoster Presentation | Abstract # 4587 | Presenter: Adanma Ayanambakkam, MD | Urothelial CancerLongitudinal analysis of ctDNA in localised and metastatic urothelial cancer\n\n\nPoster Presentation | Abstract # 4028 | Presenter: Aziz Zaanan, MD | Esophageal CancerLongitudinal ctDNA analysis during treatment (Tx) of locally advanced resectable (LAR) gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ADENOCA): the PLAGAST prospective biomarker study\n\n\nPoster Presentation | Abstract # 9564 | Presenter: Michael LaPelusa, MD | MelanomaAssociation between ctDNA and Recurrence-Free Survival (RFS) in Patients (pts) with Resected Stage III Melanoma - an Exploratory Analysis of SWOG S1404\n\n\nPoster Presentation | Abstract # 6056 | Presenter: Glenn Hanna, MD | Head and Neck Squamous Cell CarcinomaPersonalized ctDNA for monitoring disease status in HPV-negative head and neck squamous cell carcinoma\n\n\nPoster Presentation | Abstract # TPS8659 | Presenter: Yasushi Goto, MD, PhD | Lung CancerRandomized phase III study comparing suspension or continuation of PD- 1 Pathway Blockade for patients with advanced non-small-cell lung cancer (SAVE study: JCOG1701)\n\n\nPoster Presentation | Abstract # 569 | Presenter: Mridula George, MD | Breast CancerPredicting response to neoadjuvant therapy (NAT) in patients (pts) with early-stage breast cancer (BC) using ctDNA testing\n\n\nPoster Presentation | Abstract # 549 | Presenter: Marla Lipsyc-Sharf, MD | Breast CancerImpact of ctDNA surveillance on clinical care for patients with stage I-III breast cancer: Findings from a multi-institutional study.\n\n\nPoster Presentation | Abstract # 518 | Presenter: Yoichi Naito, MD | Breast CancerctDNA monitoring for breast cancer at high risk of recurrence: Interim analysis of JCOG1204A1\n\n\nPoster Presentation | Abstract # 10596 | Presenter: Sarah Lee, MD | Pan-Cancer (Empower)A targeted panel of actionable high risk hereditary cancer predisposition genes can identify patients with pathogenic/likely pathogenic variants (PVs) irrespective of meeting established NCCN testing criteria\n\nAbout Signatera\nSignatera is a personalized, tumor-informed, molecular residual disease test for patients previously diagnosed with cancer. Custom-built for each individual, Signatera uses circulating tumor DNA to detect and quantify cancer left in the body, identify recurrence earlier than standard of care tools, and help optimize treatment decisions. The test is available for clinical and research use and is covered by Medicare for patients with colorectal cancer, breast cancer, ovarian cancer and muscle invasive bladder cancer, as well as for immunotherapy monitoring of any solid tumor. Signatera has been clinically validated across multiple cancer types and indications, with published evidence in more than 60 peer-reviewed papers.\nAbout Natera\nNatera™ is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are supported by more than 200 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California. For more information, visit www.natera.com.\nForward-Looking Statements\nAll statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy and performance of our tests, or of the benefits of our tests and product offerings to patients, providers and payers. Additional risks and uncertainties are discussed in greater detail in \"Risk Factors\" in Natera’s recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com/investors and www.sec.gov.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20240523550998/en/\nContacts\nInvestor Relations: Mike Brophy, CFO, Natera, Inc., 510-826-2350, investor@natera.com Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@natera.com","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.0","shortVersion":"4.24.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2437875561"}